Bronchoneutral effects in hypertensive asthmatics--celiprolol versus chlorthalidone.
The actions of celiprolol and chlorthalidone on lung function were studied in a randomized double-blind study of 30 patients. At the end of a 4-week placebo run-in period each patient had a supine diastolic blood pressure between 90 and 115 mmHg, and a forced expiratory volume at the first second of expiration (FEV1) 50-80% of the predicted value in patients with bronchial asthma, and between 40% and 70% of the predicted value in patients with chronic airways obstruction. The active treatment period lasted 12 weeks during which patients received either celiprolol, 200-600 mg daily, or chlorthalidone 12.5-37.5 mg daily. Lung function, blood pressure and heart rate were measured and assessed every 2 weeks during active treatment. Systolic and diastolic blood pressures were reduced during treatment with both drugs, but FEV1, forced vital capacity and forced expiratory volume at 25-75% of vital capacity were not significantly altered. These results suggest that celiprolol does not adversely affect pulmonary function in hypertensive patients who also have chronic bronchial obstruction.
Dorow
P
P
Respiratory Department, Charlottenburg Clinic, Free University of Berlin, FRG.
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications* / Q000503:physiopathology; D017272:Celiprolol; D002752:Chlorthalidone / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation
D000959:Antihypertensive Agents; D011412:Propanolamines; D017272:Celiprolol; D002752:Chlorthalidone